# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer.
Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:CGEN) with a Buy and raises the price target from ...
Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.23 by 5...
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...
Stifel analyst Stephen Willey maintains Compugen (NASDAQ:CGEN) with a Buy and raises the price target from $3 to $4.